These launches are what Oelrich called “must-win battles” at Bayer as the Xarelto loss of exclusivity reaches “full swing” in ...

Bayer AG reported positive results for elinzanetant in women with or at high risk of a type of breast cancer, broadening the use case for the menopause treatment expected to launch as early as ...

BERLIN--(BUSINESS WIRE)--Bayer today announced positive topline results of the Phase III study OASIS 4 investigating elinzanetant as non-hormonal treatment for moderate to severe vasomotor ...

(RTTNews) - Bayer Aktiengesellschaft (BAYRY.PK), Thursday announced that Elinzanetant, a non-hormonal drug, has met all primary and second endpoints in the Phase III study OASIS 4, investigating ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

1. Elinzanetant meets all primary and secondary endpoints in phase 3 study OASIS 4 for treatment of moderate to severe vasomotor symptoms caused by breast cancer treatments. Bayer. News release.

Bayer only had its filing for approval of the NK-1 and NK-3 antagonist elinzanetant accepted for review in October 2024. Yet, while Bayer is playing catch-up in the menopause space, the German ...

Bayer's most recent financial performance has ... and is planning market launches for acoramidis and elinzanetant in 2025. However, while the pressure coming from Xarelto is quite certain, the ...

Elinzanetant reduced vasomotor symptoms frequency and severity in women with or at high risk of HR-positive breast cancer in ...

reinforcing Bayer’s leadership in these important therapeutic areas Investigational compound elinzanetant met all primary and secondary endpoints in Phase III study OASIS 4 for the treatment of ...